Nodal metrics after neoadjuvant therapy to refine selection for adjuvant therapy in resected PDAC

Hoshang Amirian,Ifeanyichukwu C. Ogobuiro,Gregory C. Wilson,Shishir K. Maithel,Richard A. Snyder,Alexander A. Parikh,Chet W. Hammill, Hee Jin Kim,Daniel E. Abbott,David A. Kooby, Nadeem Zafar,Michael T. LeCompte,Syed A. Ahmad,Nipun B. Merchant,Jashodeep Datta

HPB（2023）

引用 0|浏览8

暂无评分

摘要

Background: In patients with localized pancreatic ductal adenocarcinoma (PDAC) receiving neoadjuvant therapy (NAT) and resection, selection of adjuvant chemotherapy (AC) is typically guided by high-risk features on histopathologic examination (e.g., nodal positivity). We sought to evaluate the interaction between post-NAT lymph node metrics and relative benefit of AC in a multi-institutional cohort.

查看译文

关键词

neoadjuvant therapy,neoadjuvant therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要